Multidisciplinary meeting review in nonsmall cell lung cancer: a systematic review and meta-analysis
RG Stirling, A Harrison, J Huang, V Lee… - European …, 2024 - Eur Respiratory Soc
Background: Lung cancer diagnosis, staging and treatment may be enhanced by
multidisciplinary participation and presentation in multidisciplinary meetings (MDM). We …
multidisciplinary participation and presentation in multidisciplinary meetings (MDM). We …
[HTML][HTML] Clinical Applications of Endobronchial Ultrasound (EBUS) Scope: Challenges and Opportunities
D Biondini, M Tinè, U Semenzato, M Daverio… - Diagnostics, 2023 - mdpi.com
Endobronchial Ultrasound (EBUS) has been widely used to stage lung tumors and to
diagnose mediastinal diseases. In the last decade, this procedure has evolved in several …
diagnose mediastinal diseases. In the last decade, this procedure has evolved in several …
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and …
V Escudero-Vilaplana, R Collado-Borrell… - Journal of Medical …, 2023 - Taylor & Francis
Aims To assess the cost-effectiveness of adjuvant atezolizumab in the treatment of early-
stage NSCLC patients (stage II–IIIA) with expression PD-L1≥ 50% without mutations in …
stage NSCLC patients (stage II–IIIA) with expression PD-L1≥ 50% without mutations in …
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
MS Kuruvilla, G Liu, I Syed, F Gwadry-Sridhar… - Lung Cancer, 2022 - Elsevier
Objectives The ADAURA trial demonstrated the benefit of adjuvant osimertinib among
patients with resected, early-stage, epidermal growth factor receptor-mutated (EGFRm) non …
patients with resected, early-stage, epidermal growth factor receptor-mutated (EGFRm) non …
Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma
KH Lue, SC Chu, LY Wang, YC Chen, MH Li… - Annals of Nuclear …, 2022 - Springer
Objective The diagnostic performance of 18 F-FDG PET for detecting regional lymph node
metastasis in resectable lung cancer is variable, and its sensitivity for adenocarcinoma is …
metastasis in resectable lung cancer is variable, and its sensitivity for adenocarcinoma is …
[HTML][HTML] EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?
P Hofman - Cells, 2021 - mdpi.com
The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA)
non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting …
non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting …
[HTML][HTML] Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis
C Zhou, Z Jing, W Liu, Z Ma, S Liu, Y Fang - Scientific Reports, 2023 - nature.com
Molecular biomarkers have the potential to predict the recurrence risk of early-stage lung
adenocarcinoma (LUAD) after complete resection, but the study results are controversial …
adenocarcinoma (LUAD) after complete resection, but the study results are controversial …
[HTML][HTML] Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung …
Y Hao, J Yang, D Liu, H Zhang, T Ou, L Xiao… - Biomedicine & …, 2024 - Elsevier
Combination therapy has become the most important treatment for advanced non-small cell
lung cancer (NSCLC), which can significantly improve the prognosis of patients. However …
lung cancer (NSCLC), which can significantly improve the prognosis of patients. However …
Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
M Bitenc, T Cufer, I Kern, M Miklavcic… - Radiology and …, 2022 - sciendo.com
Background Treatment of early-stage non-small cell lung cancer (NSCLC) is rapidly
evolving. When introducing novelties, real-life data on effectiveness of currently used …
evolving. When introducing novelties, real-life data on effectiveness of currently used …
Concomitant Statins and the Survival of Patients with Non‐Small‐Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta‐Analysis
L Zhang, H Wang, J Tian, L Sui… - International Journal of …, 2022 - Wiley Online Library
Statins are suggested to improve cancer survival by possible anti‐inflammatory effect.
However, it remains unclear if concomitant use of statins could improve the efficacy of …
However, it remains unclear if concomitant use of statins could improve the efficacy of …